{"id":"NCT00993967","sponsor":"Santhera Pharmaceuticals","briefTitle":"Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)","officialTitle":"A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2009-10-14","resultsPosted":"2018-03-05","lastUpdate":"2018-03-05"},"enrollment":200,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Freidreich's Ataxia"],"interventions":[{"type":"DRUG","name":"idebenone","otherNames":[]}],"arms":[{"label":"Idebenone","type":"EXPERIMENTAL"}],"summary":"This is an Extension study of the MICONOS main randomised placebo-controlled trial (NCT00905268), and open to those patients completing the main study. The scientific aim of this extension study is to monitor safety and tolerability of idebenone over two years in patients with Friedreich's Ataxia.","primaryOutcome":{"measure":"Measures of Safety and Tolerability: Nature and Frequency of Adverse Events (AEs)","timeFrame":"overall study, up to 24 months","effectByArm":[{"arm":"Idebenone","deltaMin":188,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":11,"countries":["Austria","Belgium","France","Germany","Netherlands"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":200},"commonTop":["nasopharyngitis","headache","diarrhoea","nausea","influenza"]}}